Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian Biosciences : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

10/12/2021 | 07:02pm EST

Enochian BioSciences

Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS and Oncology.

© 2019EnochianBio. All rights reserved. Powered by getfused

Disclaimer

Enochian Biosciences Inc. published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 23:01:07 UTC.


ę Publicnow 2021
All news about ENOCHIAN BIOSCIENCES, INC.
12/03Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on P..
AQ
12/01ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)
AQ
11/15ENOCHIAN BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Enochian Biosciences, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
10/28Amendment to Annual Report (Form 10-K/A)
PU
10/19Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
10/18ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
10/18Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -9,71x
Yield 2021 -
Capitalization 534 M 534 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,9%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.289.15%488
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.21.78%65 758
VERTEX PHARMACEUTICALS-13.76%51 819